PPARs in the brain

HENEKA, M; LANDRETH, G

doi:10.1016/j.bbalip.2007.04.016

Cited by 319Peroxisome Proliferator-Activated ReceptorsNeuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

PPARs in the brain

HENEKA, M, LANDRETH, G·2007·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

DOI 10.1016/j.bbalip.2007.04.016

Open this paper in CoChat — free account

Abstract

The biology of peroxisome proliferator activated receptors (PPARs) in physiological and pathophysiological processes has been primarily studied in peripherial organs and tissues. Recently it became clear that PPARs play an important role for the pathogenesis of various disorders of the CNS. The finding that activation of PPARs, and in particular, the PPARgamma isoform, suppresses inflammation in peripherial macrophages and in models of human autoimmune disease, instigated the experimental evaluation of these salutary actions for several CNS disorders that have an inflammatory component. Activation of all PPAR isoforms, but especially of PPARgamma, has been found to be protective in murine in vitro and in vivo models of Multiple Sclerosis. The verification of these findings in human cells prompted the initiation of clinical studies evaluating PPARgamma activation in Multiple Sclerosis patients. Likewise, Alzheimer's disease has a prominent inflammatory component that arises in response to neurodegeneration and to extracellular deposition of beta-amyloid peptides. The fact that non steroidal anti-inflammatory drugs (NSAIDs) delay the onset and reduce the risk to develop Alzheimer's disease, while they also bind to and activate PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD may be mediated by PPARgamma. Several lines of evidence from in vitro and in vivo studies have supported this hypothesis, using Alzheimer disease related transgenic cellular and…

Integrity signals

Registry

Crossref · 10.1016/j.bbalip.2007.04.016

Cites

181 of 181 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In the brain, PPARγ agonists reduce Aβ- and cytokine-mediated neuroinflammation and neurotoxicity in vitro and in vivo.
“In the brain, PPAR␥ agonists reduce A␤-and cytokinemediated neuroinflammation and neurotoxicity in vitro (Heneka et al., 1999;Combs et al., 2000) and in vivo (for review, see Heneka and Landreth, 2007).”
From PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice (2012) · cites this paper as Heneka and Landreth, 2007

The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,422 · see citing works
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514 · see citing works
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525 · see citing works
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,079 · see citing works
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · see citing works
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523 · see citing works
World Cancer Report
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,389 · see citing works
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217 · see citing works
The WHO Classification of Tumors of the Nervous System
Kleihues, P., Louis, D. N., Scheithauer, B. W., RORKE, L. B., Reifenberger, G., Burger, P. C., & Cavenee, W. K. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.215 · Cited by 1,963 · see citing works
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y., Ruiz‐Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,960 · see citing works
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310 · see citing works
Peroxisome proliferator-activated receptor a target genes
Mandard, S., M�ller, M., & Kersten, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3216-3 · Cited by 1,222 · see citing works
Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay
Krey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0007 · Cited by 1,221 · see citing works
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207 · see citing works
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · see citing works
PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth
Rosen, E. D., & Spiegelman, B. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100034200 · Cited by 1,174 · see citing works
Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · see citing works
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089 · see citing works
PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · see citing works
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · see citing works
Immunological Aspects of Demyelinating Diseases
Martinꝉ, R., McFarland, H. F., & McFarlin, D. E. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.001101 · Cited by 1,016 · see citing works
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J. H., Berger, J. P., Chatterjee, K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 997 · see citing works
Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics
Barone, F. C., & Feuerstein, G. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199908000-00001 · Cited by 924 · see citing works
Emerging roles of PPARS in inflammation and immunity
Daynes, R. A., & Jones, D. C. (2002) · Nature reviews. Immunology · doi:10.1038/nri912 · Cited by 922 · see citing works
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
Su, C. G., Wen, X., Bailey, S. T., Jiang, W. G., Rangwala, S. M., Keilbaugh, S. A., Flanigan, A., Murthy, S., Lazar, M. A., & Wu, G. D. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7145 · Cited by 769 · see citing works
Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients
Auboeuf, D., Rieusset, J., Lluis Fajas, A., Vallier, P., Fréring, V., Riou, J. P., Staels, B., Auwerx, J. H., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diab.46.8.1319 · Cited by 699 · see citing works
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686 · see citing works
Diabetes Mellitus and Risk of Alzheimer's Disease and Dementia with Stroke in a Multiethnic Cohort
Luchsinger, J. A. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.7.635 · Cited by 682 · see citing works
Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease
Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M., Ruberg, M., Faucheux, B. A., Agid, Y., & Hirsch, É. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7531 · Cited by 678 · see citing works
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647 · see citing works
Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ)
Peters, J. M., Lee, S. S. T., Li, W., Ward, J. M., Gavrilova, O., Grueter, C. A., Reitman, M. L., Hudson, L. D., & Gonzalez, F. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5119-5128.2000 · Cited by 631 · see citing works
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. Á., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 630 · see citing works
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Przedborski, S., Jackson-Lewis, V. R., Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624 · see citing works
Dynamics of microglial activation: A confocal time-lapse analysis in hippocampal slices
Stence, N., Waite, M., & Dailey, M. E. (2001) · Glia · doi:10.1002/1098-1136(200103)33:3 · Cited by 617 · see citing works
Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone
Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Fishel, M. A., Kulstad, J. J., Green, P. S., Cook, D. G., et al. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 607 · see citing works
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582 · see citing works
Immunolocalization of peroxisome proliferator-activated receptors and retinoid x receptors in the adult rat CNS
Moreno, S., Vecchioli, S. F., & Cerù, M. P. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.064 · Cited by 581 · see citing works
Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565 · see citing works
Self-citation
Parallel SUMOylation-Dependent Pathways Mediate Gene- and Signal-Specific Transrepression by LXRs and PPARγ
Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561 · see citing works
Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat
Relton, J. K., & Rothwell, N. J. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90033-t · Cited by 548 · see citing works
Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis
Qiu, W. Q., & Folstein, M. F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.004 · Cited by 538 · see citing works
Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483 · see citing works
Self-citation
Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding
Escher, P., Braissant, O., Modak, S. B., Michalik, L., Wahli, W., & Desvergne, B. (2001) · Endocrinology · doi:10.1210/endo.142.10.8458 · Cited by 473 · see citing works
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E. J., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 470 · see citing works
Inflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470 · see citing works
Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease
Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., & Landreth, G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07504.2003 · Cited by 469 · see citing works
Self-citation
Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) Heterodimer
Desreumaux, P., Dubuquoy, L., Nutten, S., Peuchmaur, M. M., Englaro, W., Schoonjans, K., Dérijard, B., Desvergne, B., Wahli, W., Chambon, P., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.827 · Cited by 458 · see citing works
Differential Expression of Peroxisome Proliferator-Activated Receptor- , - , and - during Rat Embryonic Development
Braissant, O., & Wahli, W. (1998) · Endocrinology · doi:10.1210/endo.139.6.6049 · Cited by 454 · see citing works
Peroxisome proliferator activated receptor-alpha expression in human liver.
Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · PubMed · Cited by 448 · see citing works
Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440 · see citing works
Self-citation
Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study
Kuusisto, J., Koivisto, K. J., Mykkänen, L. M., Helkala, E.-L., Vanhanen, M., Hänninen, T., Kervinen, K., Kesäniemi, Y. A., Riekkinen, P. J., & Laakso, M. (1997) · BMJ · doi:10.1136/bmj.315.7115.1045 · Cited by 426 · see citing works
Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons
Hantraye, P., Brouillet, E., Ferrante, R. J., Palfi, S., Dolan, R., Matthews, R. T., & Beal, M. F. (1996) · Nature Medicine · doi:10.1038/nm0996-1017 · Cited by 422 · see citing works
Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 versus PPARγ1 and Activation with Retinoid X Receptor Agonists and Antagonists
Mukherjee, R., Jow, L., Croston, G. E., & Paterniti, J. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.8071 · Cited by 421 · see citing works
Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice
Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E., & Beal, M. F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020936.x · Cited by 417 · see citing works
The Role of Insulin Resistance in the Pathogenesis of Alzheimer??s Disease
Watson, G. S., & Craft, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317010-00003 · Cited by 396 · see citing works
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation
Dehmer, T., Heneka, M. T., Sastre, M., DICHGANS, J., & Schulz, J. B. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02210.x · Cited by 382 · see citing works
Self-citation
15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
Kawahito, Y., Kondo, M., Tsubouchi, Y., Hashiramoto, A., Bishop‐Bailey, D., Inoue, K., Kohno, M., Yamada, R., Hla, T., & Sano, H. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9652 · Cited by 377 · see citing works
Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G. E., Launay, J., & Hirsch, É. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 375 · see citing works
Self-citation
Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503839103 · Cited by 373 · see citing works
Self-citation
Anti‐ICAM‐1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat
Zhang, R. L., Chopp, M., Li, Y., Zaloga, C., Jiang, N., Jones, M. L., Miyasaka, M., & Ward, P. A. (1994) · Neurology · doi:10.1212/wnl.44.9.1747 · Cited by 362 · see citing works
Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase
Sastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., LEUVEN, F. V., & Heneka, M. T. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09796.2003 · Cited by 359 · see citing works
Self-citation
Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo
Dehmer, T., Lindenau, J. H., Haid, S., DICHGANS, J., & Schulz, J. B. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742213.x · Cited by 337 · see citing works
Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activity
Rieckmann, P., Albrecht, M., Kitze, B., Weber, T., Tumani, H., Broocks, A., Lüer, W., Helwig, A., & Poser, S. (1995) · Annals of Neurology · doi:10.1002/ana.410370115 · Cited by 334 · see citing works
PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes
Marx, N., Kehrle, B., Kohlhammer, K., Grüb, M., Köenig, W., Hombach, V., Libby, P., & Plutzky, J. (2002) · Circulation Research · doi:10.1161/01.res.0000014225.20727.8f · Cited by 331 · see citing works
Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04327.x · Cited by 322 · see citing works
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice
Pedersen, W. A., McMillan, P. J., Kulstad, J. J., Leverenz, J. B., Craft, S., & Haynatzki, G. R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.018 · Cited by 321 · see citing works
Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion
Collino, M., Aragno, M., Mastrocola, R., Gallicchio, M., Rosa, A. C., Dianzani, C., Danni, O., Thiemermann, C., & Fantozzi, R. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.049 · Cited by 302 · see citing works
Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.
Palakurthi, S. S., Aktaş, H., Grubissich, L., Mortensen, R. M., & Halperin, J. A. (2001) · PubMed · Cited by 301 · see citing works
Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells
Marx, N., Mach, F., Sauty, A., Leung, J. H., Sarafi, M. N., Ransohoff, R. M., Libby, P., Plutzky, J., & Luster, A. D. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6503 · Cited by 296 · see citing works
Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
Gimble, J. M., Robinson, C. E., Wu, X., Kelly, K. A., Rodriguez, B., Kliewer, S. A., Lehmann, J. M., & Morris, D. C. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09536-7 · Cited by 295 · see citing works
Peroxisome proliferator‐activated receptor‐γ agonists prevent experimental autoimmune encephalomyelitis
Feinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G. L., & Heneka, M. T. (2002) · Annals of Neurology · doi:10.1002/ana.10206 · Cited by 294 · see citing works
Self-citation
Peroxisome Proliferator-Activated Receptor-γ Agonist 15-Deoxy-Δ12,1412,14-Prostaglandin J2 Ameliorates Experimental Autoimmune Encephalomyelitis
Diab, A., Deng, C., Smith, J. D., Hussain, R. Z., Phanavanh, B., Lovett‐Racke, A. E., Drew, P. D., & Racke, M. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2508 · Cited by 291 · see citing works
Post-ischemic inflammation: molecular mechanisms and therapeutic implications
Zheng, Z., & Yenari, M. A. (2004) · Neurological Research · doi:10.1179/016164104x2357 · Cited by 290 · see citing works
Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
Yoram Vodovotz, B., Lucia, M. S., Flanders, K. C., Chesler, L., Xie, Q. W., Smith, T. W., Weidner, J. R., Mumford, R. A., Webber, R., Nathan, C., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.4.1425 · Cited by 289 · see citing works
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275 · see citing works
Peroxisome Proliferator-Activated Receptor-γ Ligands Reduce Neuronal Inducible Nitric Oxide Synthase Expression and Cell DeathIn Vivo
Heneka, M. T., Klockgether, T., & Feinstein, D. L. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-18-06862.2000 · Cited by 269 · see citing works
Self-citation
Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia
Sundararajan, S., Gamboa, J. L., Victor, N., Wanderi, E. W., Lust, W. D., & Landreth, G. E. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.021 · Cited by 266 · see citing works
Self-citation
Inhibition of Inducible Nitric Oxide Synthase by Peroxisome Proliferator-Activated Receptor Agonists: Correlation with Induction of Heme Oxygenase 1
Colville‐Nash, P., Qureshi, S. S., Willis, D., & Willoughby, D. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.978 · Cited by 241 · see citing works
Regulation of Cytokine Expression by Ligands of Peroxisome Proliferator Activated Receptors
Cunard, R. A., Ricote, M., DiCampli, D., Archer, D. C., Kahn, D. A., Glass, C. K., & Kelly, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2795 · Cited by 240 · see citing works
PRIMARY BRAIN TUMORS IN ADULTS
Chandana, S. R., Movva, S., Arora, M. L., & Singh, T. (1994) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/00132979-199401020-00005 · Cited by 235 · see citing works
Distribution of mRNAs Encoding the Peroxisome Proliferator‐Activated Receptor α, β, and γ and the Retinoid X Receptor α, β, and γ in Rat Central Nervous System
Cullingford, T. E., Bhakoo, K. K., Peuchen, S., Dolphin, C. T., Patel, R., & Clark, J. B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041366.x · Cited by 234 · see citing works
Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice
Inoue, H., Jiang, X., Katayama, T., Osada, S., Umesono, K., & Namura, S. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.001 · Cited by 232 · see citing works
The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice
Schütz, B., Reimann, J., Dumitrescu‐Ozimek, L., Kappes‐Horn, K., Landreth, G. E., Schürmann, B., Zimmer, A., & Heneka, M. T. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2038-05.2005 · Cited by 225 · see citing works
Self-citation
PPAR-γ Agonists as Regulators of Microglial Activation and Brain Inflammation
Bernardo, A., & Minghetti, L. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206780574579 · Cited by 220 · see citing works
Peroxisome Proliferator-Activated Receptor-α Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment
Deplanque, D., Gelé, P., Pétrault, O., Six, I., Furman, C., Bouly, M., Nion, S., Dupuis, B., Leys, D., Fruchart, J., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06264.2003 · Cited by 219 · see citing works
A Peroxisome Proliferator-Activated Receptor-γ Agonist Reduces Infarct Size in Transient but Not in Permanent Ischemia
Shimazu, T., Inoue, I., Araki, N., Asano, Y., Sawada, M., Furuya, D., Nagoya, H., & Greenberg, J. H. (2004) · Stroke · doi:10.1161/01.str.0000152271.21943.a2 · Cited by 218 · see citing works
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis
Kiaei, M., KIPIANI, K., CHEN, J., Calingasan, N. Y., & Beal, M. F. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.10.007 · Cited by 215 · see citing works
Constitutive Activation of Peroxisome Proliferator-activated Receptor-γ Suppresses Pro-inflammatory Adhesion Molecules in Human Vascular Endothelial Cells
Wang, N., Verna, L. K., Chen, N.-G., Chen, J., Li, H., FORMAN, B. M., & Stemerman, M. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203436200 · Cited by 208 · see citing works
Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease
Lovett‐Racke, A. E., Hussain, R. Z., Northrop, S. C., Choy, J., Rocchini, A., Matthes, L., Chavis, J. A., Diab, A., Drew, P. D., & Racke, M. K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5790 · Cited by 207 · see citing works
Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone
Luo, Y., Yin, W., Signore, A. P., Zhang, F., Hong, Z., Wang, S., Graham, S. H., & Chen, J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03758.x · Cited by 203 · see citing works
Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor γ Activation
Luna‐Medina, R., Cortés‐Canteli, M., Alonso, M., Santos, Á., Martı́nez, A., & Pérez‐Castillo, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414390200 · Cited by 191 · see citing works
Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype
Craft, S., Asthana, S., Schellenberg, G. D., Baker, L. D., Cherrier, M. M., Boyt, A., Martins, R. N., Raskind, M. A., Peskind, E. R., & Plymate, S. R. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06371.x · Cited by 191 · see citing works
Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ
Niino, M., Iwabuchi, K., Kikuchi, S., Ato, M., Morohashi, T., Ogata, A., Tashiro, K., & Onoé, K. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00285-5 · Cited by 188 · see citing works
Peroxisome proliferator-activated receptor γ is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role of Wnt signaling
Inestrosa, N. C., Godoy, J. A., Quintanilla, R. A., KOENIG, C., & Bronfman, M. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.09.032 · Cited by 187 · see citing works
Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain
Chopp, M., Li, Y., Jiang, N., Zhang, R. L., & Prostak, J. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199607000-00007 · Cited by 185 · see citing works
Peroxisome Proliferator-Activated Receptor γ Induces a Clearance Mechanism for the Amyloid-β Peptide
Espuny-Camacho, I., Serneels, L., Spittaels, K., Merchiers, P., Dominguez, D. I., & Strooper, B. D. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3987-04.2004 · Cited by 169 · see citing works
Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease
Landreth, G. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00296-2 · Cited by 169 · see citing works
Self-citation
Inhibition of TNFα attenuates infarct volume and ICAM-1 expression in ischemic mouse brain
Yang, G., Gong, C., Qin, Z., Ye, W., Mao, Y. Q., & Bertz, A.-K. (1998) · Neuroreport · doi:10.1097/00001756-199806220-00041 · Cited by 166 · see citing works
Peroxisome Proliferator-activated Receptor γ-mediated Regulation of Neural Stem Cell Proliferation and Differentiation
Wada, K., Nakajima, A., Katayama, K., Kudo, C., Shibuya, A., Kubota, N., Terauchi, Y., Tachibana, M., Miyoshi, H., Kamisaki, Y., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513786200 · Cited by 165 · see citing works
Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: Effects of the PPAR-α agonist WY14643
Collino, M., Aragno, M., Mastrocola, R., Benetti, E., Gallicchio, M., Dianzani, C., Danni, O., Thiemermann, C., & Fantozzi, R. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.04.030 · Cited by 163 · see citing works
Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender
Craft, S., Asthana, S., Schellenberg, G., Cherrier, M., Baker, L. D., Newcomer, J., Plymate, S., Latendresse, S., Petrova, A., Raskind, M., et al. (1999) · Neuroendocrinology · doi:10.1159/000054469 · Cited by 154 · see citing works
Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase
Heneka, M. T., L. Feinstein, D., Galea, E., Gleichmann, M., Wüllner, U., & Klockgether, T. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00192-7 · Cited by 150 · see citing works
Self-citation
Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease
Heneka, M. T., Wiesinger, H., Dumitrescu‐Ozimek, L., Riederer, P. F., Feinstein, D. L., & Klockgether, T. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.9.906 · Cited by 147 · see citing works
Self-citation
Interferon-γ-induced Regulation of Peroxisome Proliferator-activated Receptor γ and STATs in Adipocytes
Waite, K. J., Floyd, Z. E., Arbour-Reily, P., & Stephens, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007894200 · Cited by 145 · see citing works
Noradrenergic depletion increases inflammatory responses in brain: effects on IκB and HSP70 expression
Heneka, M. T., Gavrilyuk, V., Landreth, G. E., O’Banion, M. K., Weinberg, G. L., & Feinstein, D. L. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01694.x · Cited by 142 · see citing works
Self-citation
Altered PPARγ expression and activation after transient focal ischemia in rats
Victor, N., Wanderi, E. W., Gamboa, J. L., Zhao, X., Aronowski, J. A., Deininger, K. M., Lust, W. D., Landreth, G. E., & Sundararajan, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05037.x · Cited by 142 · see citing works
Self-citation
Effects of peroxisome proliferator‐activated receptor‐γ agonists on central nervous system inflammation
Kielian, T., & Drew, P. D. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10501 · Cited by 140 · see citing works
Neuroprotective Efficacy of the Peroxisome Proliferator-Activated Receptor δ-Selective Agonists in Vitro and in Vivo
Iwashita, A., Muramatsu, Y., Yamazaki, T., Muramoto, M., Kita, Y., Yamazaki, S., Mihara, K., Moriguchi, A., & Matsuoka, N. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.115758 · Cited by 140 · see citing works
Untitled work
(1997) · PubMed · Cited by 139 · see citing works
Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2
Kim, E. J., Kwon, K. J., Park, J.-Y., Lee, S., Moon, C., & Baik, E. J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02480-0 · Cited by 137 · see citing works
Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ
Zander, T., Kraus, J. A., Grommes, C., Schlegel, U. S., Feinstein, D. L., Klockgether, T., Landreth, G. E., Koenigsknecht-Talboo, J., & Heneka, M. T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00899.x · Cited by 135 · see citing works
Self-citation
Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
Kintscher, U., Goetze, S., Wakino, S., Kim, S., Nagpal, S., Chandraratna, R. A. S., Graf, K., Fleck, E., Hsueh, W. A., & Law, R. E. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00461-1 · Cited by 131 · see citing works
Peroxisome Proliferator-activated Receptor β Regulates Acyl-CoA Synthetase 2 in Reaggregated Rat Brain Cell Cultures
Modak, S. B., Braissant, O., Escher, P., Desvergne, B., Honegger, P., & Wahli, W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35881 · Cited by 130 · see citing works
Glitazones Differentially Regulate Primary Astrocyte and Glioma Cell Survival
Pérez‐Ortiz, J. M., Tranque, P., Vaquero, C. F., Domingo, B., Molina, F., Calvo, S., Jordán, J., Ceña, V., & Llopis, J. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308518200 · Cited by 128 · see citing works
Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer disease
Fuentealba, R. A., Farı́as, G. G., Scheu, J., Bronfman, M., Marzolo, M., & Inestrosa, N. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.07.018 · Cited by 126 · see citing works
Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis
Polak, P. E., Kalinin, S., Russo, C. D., Gavrilyuk, V., Sharp, A. J., Peters, J. M., Richardson, J. C., Willson, T. M., Weinberg, G. L., & Feinstein, D. L. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.07.006 · Cited by 125 · see citing works
An overview of the effect of linoleic and conjugated‐linoleic acids on the growth of several human tumor cell lines
Maggiora, M., Bologna, M., Cerù, M. P., Possati, L., Angelucci, A., Cimini, A., Miglietta, A., Bozzo, F., Margiotta, C., Muzio, G., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20519 · Cited by 121 · see citing works
Role of mitochondria in ultraviolet-induced oxidative stress
Gniadecki, R., Thorn, T., Vičanová, J., Petersen, A., & Wulf, H. C. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010201)80:2 · Cited by 121 · see citing works
Inflammation and acute stroke
Becker, K. J. (1998) · Current Opinion in Neurology · doi:10.1097/00019052-199802000-00008 · Cited by 120 · see citing works
Inducible Nitric Oxide Synthase Immunoreactivity in the Alzheimer Disease Hippocampus: Association with Hirano Bodies, Neurofibrillary Tangles, and Senile Plaques
Lee, S. C., Zhao, M., Hirano, A., & Dickson, D. W. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199911000-00006 · Cited by 113 · see citing works
Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons
Woods, J. W., Tanen, M. R. L., Figueroa, D. J., Biswas, C., Zycband, E., Moller, D. E., Austin, C. P., & Berger, J. P. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02515-0 · Cited by 111 · see citing works
Environmental signals and cell fate specification in premigratory neural crest
Dorsky, R. I., Moon, R. T., & Raible, D. W. (2000) · BioEssays · doi:10.1002/1521-1878(200008)22:8 · Cited by 111 · see citing works
Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke
Barone, F. C., Hillegass, L. M., Tzimas, M. N., Schmidt, D. B., Foley, J. J., White, R. F., Price, W. J., FEUERSTEIN, G. Z., Clark, R. K., Griswold, D. E., et al. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf03160109 · Cited by 111 · see citing works
Molecular Pathology of Cerebral Ischemia: Delayed Gene Expression and Strategies for Neuroprotectiona
Iadecola, C., & Ross, M. E. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48631.x · Cited by 109 · see citing works
The intracerebral application of the PPARγ‐ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain
Zhao, Y., Patzer, A., Gohlke, P., Herdegen, T., & Čulman, J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04200.x · Cited by 109 · see citing works
Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease
PEDERSEN, W., & FLYNN, E. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.003 · Cited by 108 · see citing works
Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 Cause Potent Neuroprotection after Experimental Stroke through Noncompletely Overlapping Mechanisms
Pereira, M. P., Hurtado, O., Cárdenas, A., Boscá, L., Castillo, J., Dávalos, A., Vivancos, J., Serena, J. L., Lorenzo, P. L., Lizasoaín, I., et al. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600182 · Cited by 107 · see citing works
Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway
Park, K. S., Lee, R. D., Kang, S.-K., Han, S. Y., Park, K. L., Yang, K. H., Song, Y. S., Park, H. J., Lee, Y. M., Yun, Y. P., et al. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.03.034 · Cited by 105 · see citing works
Peroxisome Proliferator-Activated Receptor-γ-Deficient Heterozygous Mice Develop an Exacerbated Neural Antigen-Induced Th1 Response and Experimental Allergic Encephalomyelitis
Bright, J. J., Natarajan, C., Muthian, G., Barak, Y., & Evans, R. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5743 · Cited by 103 · see citing works
Proinflammatory Stimulation and Pioglitazone Treatment Regulate Peroxisome Proliferator-Activated Receptor γ Levels in Peripheral Blood Mononuclear Cells from Healthy Controls and Multiple Sclerosis Patients
Klotz, L., Schmidt, M., Giese, T., Sastre, M., Knolle, P. A., Klockgether, T., & Heneka, M. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.4948 · Cited by 102 · see citing works
Self-citation
Wnt-1 dependent activation of the survival factor NF-?B in PC12 cells
Bournat, J. C., Brown, A. M. C., & Soler, A. P. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000701)61:1 · Cited by 100 · see citing works
Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor γ Agonist Treatment
Grommes, C., Landreth, G. E., Sastre, M., Beck, M., Feinstein, D. L., Jacobs, A. H., Schlegel, U. S., & Heneka, M. T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022194 · Cited by 98 · see citing works
Self-citation
Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients
Schmidt, S., Moric, E., Schmidt, M., Sastre, M., Feinstein, D. L., & Heneka, M. T. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0803402 · Cited by 96 · see citing works
Self-citation
WY14,643, a PPARα Ligand, Has Profound Effects on Immune Responses In Vivo
Cunard, R. A., DiCampli, D., Archer, D. C., Stevenson, J. L., Ricote, M., Glass, C. K., & Kelly, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6806 · Cited by 96 · see citing works
Peroxisome-proliferator-activated receptor-gamma (PPARγ) activation protects neurons from NMDA excitotoxicity
Zhao, X., Ou, Z., Grotta, J. C., Waxham, M. N., & Aronowski, J. A. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.061 · Cited by 90 · see citing works
Peroxisome proliferator activated receptor agonists
Kersten, S., & Wahli, W. (2000) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-8393-1_9 · Cited by 89 · see citing works
Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis
Weydt, P., & ̈ller, T. M. (2005) · Neuroreport · doi:10.1097/00001756-200504250-00001 · Cited by 84 · see citing works
Peroxisome proliferator-activated receptor-?: therapeutic target for diseases beyond diabetes: quo vadis?
Pershadsingh, H. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.215 · Cited by 83 · see citing works
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
Kreisler, A., Gelé, P., Wiart, J., Lhermitte, M., Destée, A., & Bordet, R. (2007) · Brain Research · doi:10.1016/j.brainres.2006.12.011 · Cited by 82 · see citing works
Role of peroxisome proliferator-activated receptor γ in amyloid precursor protein processing and amyloid β-mediated cell death
d’Abramo, C., Massone, S., Zingg, J.-M., Pizzuti, A., Marambaud, P., Piccola, B. D., Azzi, A., Marinari, U. M., Pronzato, M. A., & Ricciarelli, R. (2005) · Biochemical Journal · doi:10.1042/bj20050560 · Cited by 81 · see citing works
Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes
Cristiano, L., Bernardo, A., & Ceru`, M. P. (2001) · Journal of Neurocytology · doi:10.1023/a:1016525716209 · Cited by 80 · see citing works
Pathways of Inflammatory Activation in Alzheimers Disease: Potential Targets for Disease Modifying Drugs
Hüll, M., Lieb, K. P., & Fiebich, B. L. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023371292 · Cited by 80 · see citing works
Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells.
Han, S. W., Greene, M. E., Pitts, J., Wada, R. K., & Sidell, N. (2001) · PubMed · Cited by 77 · see citing works
The Nonthiazolidinedione PPARγ Agonist L-796,449 Is Neuroprotective in Experimental Stroke
Pereira, M. P., Hurtado, O., Cárdenas, A., Alonso‐Escolano, D., Boscá, L., Vivancos, J., Nombela, F., Leza, J. C., Lorenzo, P. L., Lizasoaín, I., et al. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000178852.83680.3c · Cited by 76 · see citing works
Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin
Schultze, K., Böck, B. C., Eckert, A., Oevermann, L., Ramacher, D., Wiestler, O. D., & Roth, W. (2006) · APOPTOSIS · doi:10.1007/s10495-006-8896-3 · Cited by 72 · see citing works
Increased Infarct Size and Lack of Hyperphagic Response after Focal Cerebral Ischemia in Peroxisome Proliferator-Activated Receptor β-Deficient Mice
Arsenijevic, D., de Bilbao, F., Plamondon, J., Paradis, E., Vallet, P. G., Richard, D., Langhans, W., & Giannakopoulos, P. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600200 · Cited by 71 · see citing works
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone
Yao, C., Lai, G., Chan, C., Cheng, A., Yang, Y., & Chuang, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21361 · Cited by 70 · see citing works
Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease
Keller, J. M., Collet, P., Bianchi, A., Huin‐Schohn, C., Krémarik, P., Bécuwe, P., Schohn, H., Domenjoud, L., & Dauça, M. (2000) · The International Journal of Developmental Biology · doi:10.1387/ijdb.11032176 · Cited by 70 · see citing works
A Peroxisome Proliferator-activated Receptor-γ Agonist, Troglitazone, Facilitates Caspase-8 and -9 Activities by Increasing the Enzymatic Activity of Protein-tyrosine Phosphatase-1B on Human Glioma Cells
Akasaki, Y., Liu, G., Matundan, H. H., Ng, H., Yuan, X., Zeng, Z., Black, K. L., & Yu, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505266200 · Cited by 70 · see citing works
Transcription Suppression of Peroxisome Proliferator-Activated Receptor γ2 Gene Expression by Tumor Necrosis Factor α via an Inhibition of CCAAT/ Enhancer-binding Protein δ during the Early Stage of Adipocyte Differentiation
Kudo, M., Sugawara, A., Uruno, A., Takeuchi, K., & Ito, S. (2004) · Endocrinology · doi:10.1210/en.2004-0180 · Cited by 69 · see citing works
Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors.
Straková, N., Ehrmann, J., Bartoš, J., Malíková, J., Doležel, J., & Kolar, Z. (2005) · PubMed · Cited by 65 · see citing works
Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways
Berge, K., Tronstad, K. J., Flindt, E. N., Rasmussen, T. H., Madsen, L., Kristiansen, K., & Berge, R. K. (2001) · Carcinogenesis · doi:10.1093/carcin/22.11.1747 · Cited by 64 · see citing works
The Synthetic Ligand of Peroxisome Proliferator-Activated Receptor-γ Ciglitazone Affects Human Glioblastoma Cell Lines
Straková, N., Ehrmann, J., Džubák, P., Bouchal, J., & Kolář, Z. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063438 · Cited by 63 · see citing works
The PPARγ ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines
Roberta Morosetti, A., Servidei, T., Massimiliano Mirabella, A., Rutella, S., Mangiola, A., Maira, G., Mastrangelo, R., & Koeffler, H. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.2.493 · Cited by 61 · see citing works
TNFα downregulates PPARδ expression in oligodendrocyte progenitor cells: Implications for demyelinating diseases
Cimini, A., Bernardo, A., Cifone, M. G., Marzio, L. D., & Loreto, S. D. (2002) · Glia · doi:10.1002/glia.10143 · Cited by 59 · see citing works
PPARγ‐dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF)
Cimini, A., Cristiano, L., Colafarina, S., Benedetti, E., Loreto, S. D., Festuccia, C., Amicarelli, F., Canuto, R. A., & Cerù, M. P. (2005) · International Journal of Cancer · doi:10.1002/ijc.21272 · Cited by 55 · see citing works
A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.
Liu, D., Zang, C., Liu, H., Possinger, K., Fan, S.-G., & Elstner, E. (2004) · PubMed · Cited by 53 · see citing works
PPARγ antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-Deoxy-Δ12,14-Prostaglandin J2
Raikwar, H. P., Muthian, G., Rajasingh, J., Johnson, C., & Bright, J. J. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.05.013 · Cited by 51 · see citing works
Peroxisome Proliferator-Activated Receptors and Liver X Receptors in Atherosclerosis and Immunity
Barish, G. D. (2006) · Journal of Nutrition · doi:10.1093/jn/136.3.690 · Cited by 50 · see citing works
Antiinflammatory properties of PPARgamma agonists following ischemia
Sundararajan, S., & Landreth, G. E. (2004) · Drug News & Perspectives · doi:10.1358/dnp.2004.17.4.829049 · Cited by 50 · see citing works
Self-citation
Effects of Thiazolidinediones on Stroke Recovery: A Case-Matched Controlled Study
Lee, J., & REDING, M. J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9138-3 · Cited by 49 · see citing works
Effects of rosiglitazone on global ischemia-induced hippocampal injury and expression of mitochondrial uncoupling protein 2
Chen, S., Wu, H.-Y., Yang, D., Lee, S.-Y., Shaw, F., Lin, T., Liou, C., & Chuang, Y. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.017 · Cited by 48 · see citing works
Effect of the peroxisome proliferator‐activated receptor β activator GW0742 in rat cultured cerebellar granule neurons
Smith, S. A., Monteith, G. R., Robinson, J. A., Venkata, N. G., May, F. J., & Roberts‐Thomson, S. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20153 · Cited by 43 · see citing works
Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system
Vecchioli, S. F., Moreno, S., & Cerù, M. P. (2001) · Journal of Neurocytology · doi:10.1023/a:1011913223541 · Cited by 38 · see citing works
Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitro
Valentiner, U., Carlsson, M., Erttmann, R., Hildebrandt, H., & Schumacher, U. (2005) · Toxicology · doi:10.1016/j.tox.2005.05.024 · Cited by 35 · see citing works
ROSIGLITAZONE, A PEROXISOME PROLIFERATOR‐ACTIVATED RECEPTOR‐γ LIGAND, REDUCES INFARCTION VOLUME AND NEUROLOGICAL DEFICITS IN AN EMBOLIC MODEL OF STROKE
Allahtavakoli, M., Shabanzadeh, A. P., Sadr, S. S., Parviz, M., & DJAHANGUIRI, B. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04486.x · Cited by 33 · see citing works
Peroxisome proliferator-activated receptors (PPARs) in health and disease.
Ehrmann, J., Vavrušová, N., Collan, Y. U., & Kolář, Z. (2002) · Biomedical Papers · doi:10.5507/bp.2002.002 · Cited by 32 · see citing works
Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
Cellai, I., Benvenuti, S., Luciani, P., Galli, A., Ceni, E., Simi, L., Baglioni, S., Muratori, M., Ottanelli, B., Serio, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603344 · Cited by 31 · see citing works
Expression of PPARγ and Its Ligand‐dependent Growth Inhibition in Human Brain Tumor Cell Lines
Kato, M., Nagaya, T., Fujieda, M., Saito, K., Yoshida, J., & Seo, H. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01304.x · Cited by 31 · see citing works
Peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes
Lee, B. C., Lee, H., & Chung, J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.08.024 · Cited by 30 · see citing works
The human semaphorin 6B gene is down regulated by PPARs
Collet, P., Domenjoud, L., Devignes, M., Murad, H., Schohn, H., & Dauça, M. (2004) · Genomics · doi:10.1016/j.ygeno.2004.01.002 · Cited by 29 · see citing works
The Nonthiazolidinedione Tyrosine-Based Peroxisome Proliferator-Activated Receptor γ Ligand GW7845 Induces Apoptosis and Limits Migration and Invasion of Rat and Human Glioma Cells
Grommes, C., Landreth, G. E., Schlegel, U. S., & Heneka, M. T. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078972 · Cited by 28 · see citing works
Self-citation
Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor γ activation induced by 15-deoxyΔ12,14-prostaglandin J2 in neuroblastoma cells
RODWAY, H. A., Hunt, A. N., Kohler, J., Postle, A. D., & Lillycrop, K. A. (2004) · Biochemical Journal · doi:10.1042/bj20040107 · Cited by 23 · see citing works
Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells.
Posch, M. G., Zang, C., Mueller, W. C., Laß, U., von Deimling, A., & Elstner, E. (2004) · PubMed · Cited by 22 · see citing works
The Cellular Response to PPARγ Ligands Is Related to the Phenotype of Neuroblastoma Cell Lines
Servidei, T., Roberta Morosetti, A., Ferlini, C., Cusano, G., Scambia, G., Mastrangelo, R., & Koeffler, H. P. (2004) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/0965040041292297 · Cited by 20 · see citing works
Arachidonic acid increases choline acetyltransferase activity in spinal cord neurons through a protein kinase C‐mediated mechanism
Chalimoniuk, M., King‐Pospisil, K., Pedersen, W. A., Małecki, A., Wylęgała, E., Mattson, M. P., Hennig, B., & Toborek, M. J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02535.x · Cited by 17 · see citing works
Human glioblastoma ADF cells express tyrosinase, L ‐tyrosine hydroxylase and melanosomes and are sensitive to L ‐tyrosine and phenylthiourea
Bonfigli, A., Zarivi, O., Colafarina, S., Cimini, A., Ragnelli, A. M., Aimola, P., Natali, P. G., Cerù, M. P., Amicarelli, F., & Miranda, M. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20603 · Cited by 15 · see citing works
Regulation of cellular processes by PPARγ ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression
Emmans, V. C., RODWAY, H. A., Hunt, A. N., & Lillycrop, K. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320840 · Cited by 15 · see citing works
Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.
van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7 · see citing works
Self-citation
P1-397 Pioglitazone in Alzheimer's disease: rationale and clinical trial design
Geldmacher, D., & Landreth, G. E. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80709-7 · Cited by 2 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Alzheimer's disease: strategies for disease modification
Citron, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2896 · Cited by 1,060 · see citing works
The Peroxisome Proliferator-Activated Receptor: A Family of Nuclear Receptors Role in Various Diseases
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017 · see citing works
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779 · see citing works
Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480 · see citing works
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
de la Monte, S. M. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 446 · see citing works
Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation
Villapol, S. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 372 · see citing works
PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice
Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326 · see citing works
Self-citation
Fish, docosahexaenoic acid and Alzheimer’s disease
Cunnane, S. C., Plourde, M., Pifferi, F., Bégin, M. E., Féart, C., & Barberger‐Gateau, P. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.04.001 · Cited by 316 · see citing works
Stress as a neuroinflammatory condition in brain: Damaging and protective mechanisms
García‐Bueno, B., Caso, J. R., & Leza, J. C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.04.001 · Cited by 280 · see citing works
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G. E., Jiang, Q., Mandrekar, S., & Heneka, M. T. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277 · see citing works
Self-citation
Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimerʼs Disease
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265 · see citing works
Localization of PPAR isotypes in the adult mouse and human brain
Warden, A. S., Truitt, J., Merriman, M., Ponomareva, O. Y., Jameson, K. G., Ferguson, L. B., Mayfield, R. D., & Harris, R. A. (2016) · Scientific Reports · doi:10.1038/srep27618 · Cited by 243 · see citing works
Marine omega‐3 (n‐3) phospholipids: A comprehensive review of their properties, sources, bioavailability, and relation to brain health
Ahmmed, M. K., Ahmmed, F., Tian, H. S., Carne, A., & Bekhit, A. E. A. (2019) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12510 · Cited by 245 · see citing works
Evidence for impaired amyloid β clearance in Alzheimer's disease
Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., & Landreth, G. E. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt187 · Cited by 234 · see citing works
Self-citation
Inflammatory Aspects of Alzheimer Disease and Other Neurodegenerative Disorders
Schwab, C., & McGeer, P. L. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13402 · Cited by 234 · see citing works
Stress-induced neuroinflammation: mechanisms and new pharmacological targets
Munhoz, C. D., García‐Bueno, B., Madrigal, J. L. M., Lepsch, L. B., Scavone, C., & Leza, J. C. (2008) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2008001200001 · Cited by 231 · see citing works
Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation
Turnquist, C., Harris, B. T., & Harris, C. C. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa057 · Cited by 224 · see citing works
Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPARγ expression in cultured astrocytes
Valles, S. L., Dolz-Gaiton, P., Gambini, J., Borras, C., LLoret, A., Pallardo, F. V., & Viña, J. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.044 · Cited by 186 · see citing works
Effect of pioglitazone medication on the incidence of dementia
Heneka, M. T., Fink, A., & Doblhammer, G. (2015) · Annals of Neurology · doi:10.1002/ana.24439 · Cited by 185 · see citing works
Self-citation
Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia
García‐Bueno, B., Bioque, M., MacDowell, K. S., Barcones, M. F., Martínez‐Cengotitabengoa, M., Pina‐Camacho, L., Rodríguez–Jiménez, R., Sáiz, P. A., Castro, C., Lafuente, A., et al. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt001 · Cited by 177 · see citing works
BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer’s disease
Chami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168 · see citing works
Fatty Acid Signaling Mechanisms in Neural Cells: Fatty Acid Receptors
Falomir‐Lockhart, L. J., Cavazzutti, G. F., Giménez, E., & Toscani, A. M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00162 · Cited by 162 · see citing works
Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5Y<i><sup>APP+</sup></i> Cells Through PPARγ Involvement
Scuderi, C., Steardo, L., & Esposito, G. (2014) · Phytotherapy Research · doi:10.1002/ptr.5095 · Cited by 161 · see citing works
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities
Youssef, J., & Badr, M. Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01383.x · Cited by 156 · see citing works
Therapeutic Strategies for Treatment of Inflammation-related Depression
Adžić, M., Brkic, Z., Mitić, M., Francija, E., Jovicic, M. J., Radulović, J., & Marić, N. P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 156 · see citing works
Interference of pollutants with PPARs: endocrine disruption meets metabolism
Casals‐Casas, C., Feige, J. N., & Desvergne, B. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.207 · Cited by 156 · see citing works
Pioglitazone Adjunctive Therapy for Moderate-to-Severe Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Trial
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153 · see citing works
Palmitoylethanolamide in CNS health and disease
Raso, G. M., Russo, R., Calignano, A., & Meli, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.05.006 · Cited by 148 · see citing works
Cinnamic acid activates PPARα to stimulate Lysosomal biogenesis and lower Amyloid plaque pathology in an Alzheimer's disease mouse model
Chandra, S., Roy, A., Jana, M., & Pahan, K. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.007 · Cited by 149 · see citing works
Ketogenic diet-induced peroxisome proliferator-activated receptor-γ activation decreases neuroinflammation in the mouse hippocampus after kainic acid-induced seizures
Jeong, E. A., Jeon, B. T., Shin, H. J., Kim, N., Lee, D. H., Kim, H. J., Kang, S. S., Cho, G. J., Choi, W. S., & Roh, G. S. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.001 · Cited by 146 · see citing works
PPAR: a therapeutic target in Parkinson’s disease
Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 147 · see citing works
Activation of Nuclear PPARγ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking
Stopponi, S., Somaini, L., Cippitelli, A., Cannella, N., Braconi, S., Kallupi, M., Ruggeri, B., Heilig, M. A., Demopulos, G. A., Gaitanaris, G., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.010 · Cited by 134 · see citing works
The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation
Iannotti, F. A., & Vitale, R. M. (2021) · Cells · doi:10.3390/cells10030586 · Cited by 132 · see citing works
Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) and Neurodegenerative Disorders
Chen, Y., Wu, J., Tsai, H.-D., Huang, C., Chen, J.-J., Sun, G. Y., & Lin, T. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8259-8 · Cited by 127 · see citing works
Nuclear receptors as therapeutic targets for Alzheimer's disease
Mandrekar-Colucci, S., & Landreth, G. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.594043 · Cited by 126 · see citing works
Self-citation
Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells
Quintanilla, R. A., Jin, Y. N., Fuenzalida, K. M., Bronfman, M., & Johnson, G. V. W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804291200 · Cited by 126 · see citing works
Molecular mechanism of PPAR in the regulation of age-related inflammation
Chung, J. H., Seo, A. Y., Chung, S. W., Kim, M. K., Leeuwenburgh, C., Yu, B. P., & Chung, H. Y. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.01.001 · Cited by 124 · see citing works
PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation
Zolezzi, J. M., Santos, M. J., Candia, S. B., Pinto, C., Godoy, J. A., & Inestrosa, N. C. (2017) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12320 · Cited by 122 · see citing works
Pleiotropic Role of PPAR γ in Intracerebral Hemorrhage: An Intricate System Involving Nrf2, RXR , and NF ‐κB
Zhao, X., Gonzales, N. R., & Aronowski, J. A. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12350 · Cited by 121 · see citing works
Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship
Naim, M. J., Alam, M. J., Ahmad, S., Nawaz, F., Shrivastava, N., Sahu, M., & Alam, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.031 · Cited by 119 · see citing works
Polyunsaturated fatty acids and endocannabinoids in health and disease
Freitas, H. R., Isaac, A. R., Malcher‐Lopes, R., Diaz, B. L., Trevenzoli, I. H., & Reis, R. A. D. M. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1347373 · Cited by 116 · see citing works
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression
Kashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116 · see citing works
Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation
MacDowell, K. S., García‐Bueno, B., Madrigal, J. L. M., Parellada, M., Arango, C., Micó, J. A., & Leza, J. C. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001775 · Cited by 114 · see citing works
Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α
Scuderi, C., Valenza, M., Stecca, C., Esposito, G., Carratù, M. R., & Steardo, L. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-49 · Cited by 112 · see citing works
Icariin attenuates cerebral ischemia–reperfusion injury through inhibition of inflammatory response mediated by NF-κB, PPARα and PPARγ in rats
Xiong, D., Deng, Y., Huang, B., Yin, C., Liu, B., Shi, J., & Gong, Q. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.11.035 · Cited by 103 · see citing works
Role of platelets in neuroinflammation: a wide-angle perspective
Horstman, L. L., Jy, W., Ahn, Y. S., Zivadinov, R., Maghzi, A. H., Etemadifar, M., Alexander, J. S., & Minagar, A. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-10 · Cited by 104 · see citing works
May Diet and Dietary Supplements Improve the Wellness of Multiple Sclerosis Patients? A Molecular Approach
Riccio, P., Rossano, R., & Liuzzi, G. M. (2010) · Autoimmune Diseases · doi:10.4061/2010/249842 · Cited by 101 · see citing works
Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents
Youssef, A., White, M. S., Villanueva, E. B., El‐Ashmawy, I. M., & Klegeris, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.021 · Cited by 100 · see citing works
Effects of Bisphenol-A and Other Endocrine Disruptors Compared With Abnormalities of Schizophrenia: An Endocrine-Disruption Theory of Schizophrenia
Brown, J. S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm147 · Cited by 100 · see citing works
The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
Gray, E., Ginty, M., Kemp, K. C., Scolding, N. J., & Wilkins, A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-63 · Cited by 98 · see citing works
PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease
Barbiero, J. K., Santiago, R. M., Tonin, F. S., Boschen, S. L., da Silva, L. M., Werner, M. F. D. P., Cunha, C. D., Lima, M. M. S., & Vital, M. A. B. F. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.02.009 · Cited by 97 · see citing works
Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases
Calsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93 · see citing works
Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy
Simeone, T. A., Matthews, S. A., Samson, K. K., & Simeone, K. A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.08.006 · Cited by 92 · see citing works
Towards Retinoid Therapy for Alzheimers Disease
Shudo, K., Fukasawa, H., Nakagomi, M., & Yamagata, N. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486581 · Cited by 91 · see citing works
The role of polyunsaturated fatty acids and GPR40 receptor in brain
Khan, M. Z., & He, L. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.013 · Cited by 89 · see citing works
Anti-apoptotic Actions of PPAR-γ Against Ischemic Stroke
Fong, W.-H., Tsai, H., Chen, Y.-C., Wu, J., & Lin, T. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8103-y · Cited by 87 · see citing works
Microglia and Astrocyte Activation by Toll‐Like Receptor Ligands: Modulation by PPAR‐γ Agonists
Gurley, C. M., Nichols, J. R., Liu, S., Phulwani, N. K., Esen, N., & Kielian, T. (2008) · PPAR Research · doi:10.1155/2008/453120 · Cited by 84 · see citing works
Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses
Aleshin, S. E., Strokin, M., Sergeeva, M. G., & Reiser, G. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.06.012 · Cited by 82 · see citing works
Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool
Quintão, N. L. M., Santin, J. R., Stoeberl, L. C., Corrêa, T. P., Melato, J., & da Costa, R. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00907 · Cited by 81 · see citing works
Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer’s Disease
Saavedra, J. M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0327-y · Cited by 81 · see citing works
Fatty Acids, Antioxidants and Physical Activity in Brain Aging
Freitas, H. R., Ferreira, G. C., Trevenzoli, I. H., Oliveira, K. J., & Reis, R. A. D. M. (2017) · Nutrients · doi:10.3390/nu9111263 · Cited by 82 · see citing works
The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia
Martínez‐Gras, I., Perez‐Nievas, B. G., García‐Bueno, B., Madrigal, J. L. M., Andres, E. M., Rodríguez–Jiménez, R., Hoenicka, J., Palomo, T., Rubio, G., & Leza, J. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.018 · Cited by 80 · see citing works
PPAR agonists regulate brain gene expression: Relationship to their effects on ethanol consumption
Ferguson, L. B., Most, D., Blednov, Y. A., & Harris, R. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.024 · Cited by 78 · see citing works
Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice
Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N. N., Calingasan, N. Y., Yang, L., Tampellini, D., Starkov, A. A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds355 · Cited by 78 · see citing works
Assay of vtg, ERs and PPARs as endpoint for the rapid in vitro screening of the harmful effect of Di-(2-ethylhexyl)-phthalate (DEHP) and phthalic acid (PA) in zebrafish primary hepatocyte cultures
Maradonna, F., Evangelisti, M., Gioacchini, G., Migliarini, B., Olivotto, I., & Carnevali, O. (2012) · Toxicology in Vitro · doi:10.1016/j.tiv.2012.09.018 · Cited by 74 · see citing works
Therapeutic potential of nuclear receptor agonists in Alzheimer's disease
Moutinho, M., & Landreth, G. E. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075556 · Cited by 75 · see citing works
Self-citation
Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer’s Disease
Govindarajulu, M., Pinky, P. D., Bloemer, J., Ghanei, N., Suppiramaniam, V. D., & Amin, R. (2018) · PPAR Research · doi:10.1155/2018/2010675 · Cited by 75 · see citing works
Peroxisome proliferator‐activated receptor γ ligands regulate neural stem cell proliferation and differentiation in vitro and in vivo
Morales-Garcia, J. A., Luna‐Medina, R., Alfaro‐Cervelló, C., Cortés‐Canteli, M., Santos, Á., García‐Verdugo, J. M., & Pérez‐Castillo, A. (2010) · Glia · doi:10.1002/glia.21101 · Cited by 72 · see citing works
Peroxisome Proliferator-Activated Receptor (PPAR)-γ Positively Controls and PPARα Negatively Controls Cyclooxygenase-2 Expression in Rat Brain Astrocytes through a Convergence on PPARβ/δ via Mutual Control of PPAR Expression Levels
Aleshin, S. E., Grabeklis, S. A., Hanck, T., Sergeeva, M. G., & Reiser, G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056010 · Cited by 72 · see citing works
Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease
Hughes, B., & Herron, C. E. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2513-z · Cited by 72 · see citing works
Expression of E‐FABP in PC12 cells increases neurite extension during differentiation: involvement of n‐3 and n‐6 fatty acids
Liu, J., Almaguel, F. G., Bu, L., León, D. D., & León, M. A. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05507.x · Cited by 71 · see citing works
Effects and Underlying Mechanisms of Bioactive Compounds on Type 2 Diabetes Mellitus and Alzheimer’s Disease
Li, R., Zhang, Y., Rasool, S., Geetha, T., & Babu, J. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8165707 · Cited by 72 · see citing works
Role of the peroxisome proliferator-activated receptors (PPAR)-α, β/δ and γ triad in regulation of reactive oxygen species signaling in brain
Aleshin, S. E., & Reiser, G. (2013) · Biological Chemistry · doi:10.1515/hsz-2013-0215 · Cited by 70 · see citing works
Effects of the PPAR- α Agonist Fenofibrate on Acute and Short-Term Consequences of Brain Ischemia
Ouk, T., Gautier, S., Pétrault, M., Montaigne, D., Maréchal, X., Masse, I., Devedjian, J.-C., Deplanque, D., Bastide, M., Nevière, R., et al. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.233 · Cited by 69 · see citing works
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study
Lu, C.-H., Yang, C., Li, C., Hsieh, C., & Ou, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4499-5 · Cited by 70 · see citing works
Role of Non-Neuronal Cells in Body Weight and Appetite Control
Argente-Arizón, P., Freire‐Regatillo, A., Argente, J., & Chowen, J. A. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00042 · Cited by 68 · see citing works
Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study
Bohlken, J., Jacob, L., & Kostev, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180808 · Cited by 67 · see citing works
Plant derived omega-3-fatty acids protect mitochondrial function in the brain
Eckert, G. P., Franke, C., Nöldner, M., Rau, O., Wurglics, M., Schubert‐Zsilavecz, M., & Müller, W. E. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.005 · Cited by 67 · see citing works
Neuroinflammation in Alzheimer's disease: an understanding of physiology and pathology
Obulesu, M., & Jhansilakshmi, M. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2013.831852 · Cited by 65 · see citing works
Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer’s Disease via Peroxisome Proliferator-Activated Receptor α
Chandra, S., & Pahan, K. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190104 · Cited by 68 · see citing works
PPAR-Alpha Agonists as Novel Antiepileptic Drugs: Preclinical Findings
Puligheddu, M., Pillolla, G., Melis, M., Lecca, S., Marrosu, F., Montis, M. G. D., Scheggi, S., Carta, G., Murru, E., Aroni, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064541 · Cited by 65 · see citing works
Brain histological changes in young mice submitted to diets with different ratios of n-6/n-3 polyunsaturated fatty acids during maternal pregnancy and lactation
Tian, C., Fan, C., Liu, X., Xu, F., & Qi, K. (2011) · Clinical Nutrition · doi:10.1016/j.clnu.2011.03.002 · Cited by 65 · see citing works
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
García, C., Gómez‐Cañas, M., Burgaz, S., Palomares, B., Gómez‐Gálvez, Y., Palomo‐Garo, C., Campo, S., Ferrer-Hernández, J., Pavicic, C., Navarrete, C. M., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1060-5 · Cited by 65 · see citing works
The role of astrocytes in the hypothalamic response and adaptation to metabolic signals
Chowen, J. A., Argente-Arizón, P., Freire‐Regatillo, A., Frago, L. M., Horváth, T. L., & Argente, J. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.001 · Cited by 63 · see citing works
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61 · see citing works
PPARγ and Cognitive Performance
d’Angelo, M., Castelli, V., Catanesi, M., Antonosante, A., Dominguez-Benot, R., Ippoliti, R., Benedetti, E., & Cimini, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205068 · Cited by 59 · see citing works
Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: Possible neuroprotective mechanisms
Bhateja, D., Dhull, D. K., Gill, A., Sidhu, A., Sharma, S., Reddy, B. V. K., & Padi, S. S. V. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.029 · Cited by 60 · see citing works
PPARγ transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons
Du, J., Zhang, L., Liu, S., Zhang, C., Huang, X., Li, J., Zhao, N., & Wang, Z. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.047 · Cited by 60 · see citing works
Fenofibrate, a peroxisome proliferator–activated receptor‐α agonist, exerts anticonvulsive properties
Porta, N., Vallée, L., Lecointe, C., Bouchaert, E., Staels, B., Bordet, R., & Auvin, S. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01901.x · Cited by 60 · see citing works
Inflammation and the Redox‐sensitive AGE–RAGE Pathway as a Therapeutic Target in Alzheimer's Disease
Maczurek, A. E., Shanmugam, K., & Münch, G. W. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1433.026 · Cited by 60 · see citing works
Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: A preclinical stroke trial
Čulman, J., Nguyen-Ngoc, M., Glatz, T., Gohlke, P., Herdegen, T., & Zhao, Y. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.09.003 · Cited by 59 · see citing works
Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases
Maria, A. A., Moreno-Ramos, O. A., & Haider, N. B. (2015) · Journal of Experimental Neuroscience · doi:10.4137/jen.s25480 · Cited by 60 · see citing works
Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases
Assaf, N., El-Shamarka, M. E.-S., Salem, N. A., Khadrawy, Y. A., & Sayed, N. S. E. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109793 · Cited by 59 · see citing works
Regulation of peroxisome proliferator‐activated receptors (PPAR) α and ‐γ of rat brain astrocytes in the course of activation by toll‐like receptor agonists
Chistyakov, D. V., Aleshin, S. E., Astakhova, A. A., Sergeeva, M. G., & Reiser, G. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13101 · Cited by 58 · see citing works
Bezafibrate, a Peroxisome Proliferator-Activated Receptors Agonist, Decreases Body Temperature and Enhances Electroencephalogram Delta-Oscillation during Sleep in Mice
Chikahisa, S., Tominaga, K., Kawai, T., Kitaoka, K., Oishi, K., Ishida, N., Rokutan, K., & Séi, H. (2008) · Endocrinology · doi:10.1210/en.2008-0285 · Cited by 57 · see citing works
INFERNO: inferring the molecular mechanisms of noncoding genetic variants
Amlie‐Wolf, A., Tang, M., Mlynarski, E. E., Kuksa, P. P., Valladares, O., Katanić, Ž., Tsuang, D. W., Brown, C. D., Schellenberg, G. D., & Wang, L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky686 · Cited by 56 · see citing works
Therapeutic targets of brain insulin resistance in sporadic Alzheimer s disease
de la Monte, S. M. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e482 · Cited by 56 · see citing works
Elucidating the Neuroprotective Role of PPARs in Parkinson’s Disease: A Neoteric and Prospective Target
Behl, T., Madaan, P., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Al‐Harrasi, A., Chigurupati, S., Alrashdi, I., & BUNGAU, S. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810161 · Cited by 56 · see citing works
PPAR-γ Agonist Azelaoyl PAF Increases Frataxin Protein and mRNA Expression. New Implications for the Friedreich’s Ataxia Therapy
Marmolino, D., Acquaviva, F., Pinelli, M., Monticelli, A., Castaldo, I., Filla, A., & Cocozza, S. (2008) · The Cerebellum · doi:10.1007/s12311-008-0087-z · Cited by 56 · see citing works
The Peroxisome Proliferator-activated Receptor γ (PPARγ) Controls Natural Protective Mechanisms against Lipid Peroxidation in Amyotrophic Lateral Sclerosis
Benedusi, V., Martorana, F., Brambilla, L., Maggi, A. C., & Rossi, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366419 · Cited by 56 · see citing works

Drug Insight: effects mediated by peroxisome proliferator-activated receptor-γ in CNS disorders
Heneka, M. T., Landreth, G. E., & Hüll, M. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0586 · Cited by 96 · see citing works
Self-citation
PPARs in Alzheimer′s Disease
Kummer, M. P., & Heneka, M. T. (2008) · PPAR Research · doi:10.1155/2008/403896 · Cited by 78 · see citing works
Self-citation
doi:10.1155/2008/403896 Review Article PPARs in Alzheimer’s Disease
Kummer, M. P., & Heneka, M. T. (2008)
Self-citation
Chapter 22. PPARγ in Alzheimer's Disease
Heneka, M. T., & Kummer, M. P. (2010) · RSC drug discovery/RSC drug discovery series · doi:10.1039/9781849731072-00153
Self-citation
Impact and Therapeutic Potential of PPARs in Alzheimers Disease
Heneka, M. T., Reyes-Irisarri, E., Hull, M. J., & Kummer, M. P. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376325 · Cited by 124 · see citing works
Self-citation

Authors: HENEKA, M., & LANDRETH, G.
Affiliations: University of Münster (DE)
Case Western Reserve University (US)
Corresponding author: HENEKA, M
ORCID: HENEKA, M
LANDRETH, G
Venue: Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Publisher: Elsevier BV
Published: 2007-08
Volume: 1771
Issue: 8
Pages: 1031-1045
ISSN: 1388-1981 (ISSN-L)
DOI: 10.1016/j.bbalip.2007.04.016
OpenAlex: W2054685711
Cited by: 317
References: 181
Citations by year: 2026: 4 · 2025: 13 · 2024: 16 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 10 · 2019: 20 · 2018: 13 · 2017: 20 · 2016: 17 · 2015: 16 · 2014: 21 · 2013: 18 · 2012: 21
FWCI: 9.13
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (publishedVersion)
PubMed (publishedVersion)
Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords: peroxisome proliferator-activated receptors, PPARγ, brain, neuroinflammation, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, neurodegeneration, amyloid-beta, nonsteroidal anti-inflammatory drugs, PPAR agonists, neuroprotection, central nervous system development
MeSH terms: Animals, Brain, Brain Neoplasms, Central Nervous System Diseases, Brain Ischemia, Encephalomyelitis, Autoimmune, Experimental, Humans, Neurodegenerative Diseases, Peroxisome Proliferator-Activated Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PPARs in the brain

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks